Potential mechanisms of resistance to venetoclax and strategies to circumvent it.
about
Combined venetoclax and alvocidib in acute myeloid leukemia.Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth.Targeting Mitochondrial Bioenergetics as a Therapeutic Strategy for Chronic Lymphocytic Leukemia.Hematologic Tumor Cell Resistance to the BCL-2 Inhibitor Venetoclax: A Product of Its Microenvironment?
P2860
Potential mechanisms of resistance to venetoclax and strategies to circumvent it.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Potential mechanisms of resistance to venetoclax and strategies to circumvent it.
@ast
Potential mechanisms of resistance to venetoclax and strategies to circumvent it.
@en
type
label
Potential mechanisms of resistance to venetoclax and strategies to circumvent it.
@ast
Potential mechanisms of resistance to venetoclax and strategies to circumvent it.
@en
prefLabel
Potential mechanisms of resistance to venetoclax and strategies to circumvent it.
@ast
Potential mechanisms of resistance to venetoclax and strategies to circumvent it.
@en
P2093
P2860
P1433
P1476
Potential mechanisms of resistance to venetoclax and strategies to circumvent it.
@en
P2093
Chang H Park
Joel D Leverson
Kenneth B Idler
Lisa Roberts Rapp
Lloyd T Lam
Morey L Smith
Paul Hessler
Stephen K Tahir
P2860
P2888
P356
10.1186/S12885-017-3383-5
P407
P577
2017-06-02T00:00:00Z
P6179
1085763268